While previous studies have shown that CD8+ T cells, along with other biomarkers such as PD-L1 expression, tumor mutation burden (TMB), and human leukocyte antigen (HLA) class I expression, can predict response to ICIs in patients with NSCLC25–27, our study demonstrated that the ratio of CD8+ T cells to total T cells alone was not able to predict the response (37.65% ± 9.88% vs. 28.63% ± 12.38%, p = 0.059; Fig. 3g). This evidence concerns the gene CD8A and neoplasm.